Nexalin Technology (NXL) EBITDA (2021 - 2026)

Nexalin Technology has reported EBITDA for 6 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 5.5% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$8.3 million (up 2.61% YoY), and the FY2025 full-year result was -$8.2 million, down 8.07% from the prior year.
• EBITDA for Q1 2026 stood at -$2.1 million, up from -$2.4 million in the prior quarter.
• The five-year high for EBITDA was -$135401.0 in Q3 2022, with the low at -$2.8 million in Q4 2024.
• Average EBITDA over 5 years is -$1.4 million, with a median of -$1.3 million recorded in 2024.
• Year-over-year, EBITDA soared 92.46% in 2022 and sank 1620.43% in 2023.
• Tracing NXL's EBITDA over 5 years: stood at -$693364.0 in 2022, then decreased by 12.77% to -$781874.0 in 2023, then slumped by 262.39% to -$2.8 million in 2024, then gained by 16.16% to -$2.4 million in 2025, then increased by 11.73% to -$2.1 million in 2026.
• The last three EBITDA figures came in at -$2.1 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.

Peer Comparison